Distributors may suffer from credit crunch

The big three U.S. drug distributors--Cardinal Health, McKesson and AmerisourceBergen--are heading into their seasonal year-end inventory ramp-up with less cash and tougher credit market conditions relative to prior years, according to Moody's Investors Service. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.